

#3
PATENTS 2-20-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Leonard Harrison, et al

Examiner: Unassigned

Serial No.: Unassigned

Docket: 10308B

Filed: Herewith

Dated: January 7, 2002

For: IMMUNOREACTIVE AND
IMMUNOTHERAPEUTIC MOLECULES

J1040 U.S. PTO
10/040815
01/07/02

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is respectfully requested that the following disclosures, which are also listed on the attached form PTO-1449 be made of record in the above-identified case.

1. WO 92/05446, published April 2, 1992;

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number:
Date of Deposit:

EV 052766565 US
January 7, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Dated: January 7, 2002


Michelle Mustafa

2. WO 92/14485, published September 3, 1992;
3. WO 92/20811, published November 26, 1992;
4. WO 94/12529, published June 9, 1994;
5. WO 95/07464, published March 16, 1995;
6. WO 95/07992, published March 23, 1995;
7. Mauch, et al., (1992), "Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients", Eur J.Biochem, vol 212:597-603; and
8. Daw et al., (1995), "Two Distinct Glutamic Acid Decarboxylase Auto-Antibody Specificities in IDDM Target Different Epitopes" Diabetes, Vol:44, pp 216-220.

Pursuant to 37 C.F.R. §1.98(d), copies of the above listed publications are not provided, as the references were previously submitted to the Examiner in connection with the parent case, Serial No. 08/663,272 filed on November 25, 1996

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herewith may be material to the examination of the present application as defined under 35 U.S.C. §1.56(a).

Inasmuch as this Information Disclosure Statement is being filed prior to the issuance of a first Office Action on the merits with respect to the above-identified application, no fee or certificate is due.

Respectfully submitted,


Leopold Presser
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
PIB/LP:dg

Atty. Docket No.
10308B

Serial No.

**LIST OF PRIOR ART
CITED BY APPLICANT**

Applicants

Leonard Harrison, et al.

Filing Date

January 7, 2002

Group

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						
	AD						
	AE						

		Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	WO 92/05446	4/2/92	PCT				
	2.	WO 92/14485	9/3/92	PCT				
	3.	WO 92/20811	11/26/92	PCT				
	4.	WO 94/12529	6/9/94	PCT				
	5.	WO 95/07464	3/16/95	PCT				
	6.	WO 95/07992	3/23/95	PCT				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	7.	Mauch, et al., (1992), "Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients", Eur J.Biochem, vol 212:597-603
	8.	Daw et al., (1995), "Two Distinct Glutamic Acid Decarboxylase Auto-Antibody Specificities in IDDM Target Different Epitopes" <u>Diabetes</u> , Vol:44, pp 216-220

EXAMINER

DATE CONSIDERED

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.